Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 56, Issue 19, Pages 7501-7515Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm401088k
Keywords
-
Categories
Ask authors/readers for more resources
The bromo and extra C-terminal domain (BET) family of bromodomains are involved in binding epigenetic marks on histone proteins, more specifically acetylated lysine residues. This paper describes the discovery and structure activity relationships (SAR) of potent benzodiazepine inhibitors that disrupt the function of the BET family of bromodomains (BRD2, BRD3, and BRD4). This work has yielded a potent, selective compound I-BET762 that is now under evaluation in a phase I/II clinical trial for nuclear protein in testis (NUT) midline carcinoma and other cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available